Daily vs every other day administration of G-CSF following autologous peripheral stem cell transplantation: A prospective randomized study

Ozkan H. A., Ozer U. G., BAL C., Gulbas Z.

TRANSFUSION AND APHERESIS SCIENCE, vol.49, no.2, pp.163-167, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 49 Issue: 2
  • Publication Date: 2013
  • Doi Number: 10.1016/j.transci.2013.01.019
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.163-167
  • Keywords: Granulocyte-colony stimulating factor, Every other day administration, Hematopoietic recovery, Autologous peripheral stem cell transplantation, COLONY-STIMULATING FACTOR, BONE-MARROW-TRANSPLANTATION, HIGH-DOSE CHEMOTHERAPY, VERSUS-HOST-DISEASE, NEUTROPHIL ENGRAFTMENT, LYMPHOID MALIGNANCIES, RHG-CSF, BLOOD, TRIAL, RECOVERY
  • Eskisehir Osmangazi University Affiliated: Yes


The purpose of the study was to evaluate whether every other day administration of G-CSF was as safe and efficient as daily administration of G-CSF on neutrophil engraftment following autologous peripheral stem cell transplantation (APSCT). Duration of G-CSF administration, incidence of blood stream infections, duration of febrile neutropenia, duration of non-prophylactic antibiotic therapy, transfusion requirements, duration of hospitalization and G-CSF costs were also studied. Forty-seven patients with diagnosis of lymphoma and multiple myeloma undergoing APSCT were randomized to receive post-transplant daily or every other day G-CSF therapy both beginning on day +1. Both groups were comparable with regard to patient characteristics. There was no significant difference in time to neutrophil engraftment (p = 0.31). The duration of G-CSF administration was significantly less in the every other day group (p < 0.001). There were no detectable differences seen in the number of febrile days, duration of non-prophylactic antibiotics, the incidence of blood stream infections, transfusion requirements and the duration of hospitalization. There was a trend towards a faster platelet recovery in the every other day group, although the difference was not statistically significant (p = 0.059). The number of doses of G-CSF used per transplant is significantly reduced, resulting in a significant reduction in drug costs. (C) 2013 Elsevier Ltd. All rights reserved.